NZ207622A - Xylane sulphates and pharmaceutical compositions - Google Patents

Xylane sulphates and pharmaceutical compositions

Info

Publication number
NZ207622A
NZ207622A NZ207622A NZ20762284A NZ207622A NZ 207622 A NZ207622 A NZ 207622A NZ 207622 A NZ207622 A NZ 207622A NZ 20762284 A NZ20762284 A NZ 20762284A NZ 207622 A NZ207622 A NZ 207622A
Authority
NZ
New Zealand
Prior art keywords
xylane
solution
weight
sulfatation
xxx
Prior art date
Application number
NZ207622A
Other languages
English (en)
Inventor
J-P Maffrand
E Vallee
J-M Pereillo
A Bayol
J Lansen
Original Assignee
Sanofi Sa
Anic Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Anic Spa filed Critical Sanofi Sa
Publication of NZ207622A publication Critical patent/NZ207622A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/14—Hemicellulose; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0057—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Saccharide Compounds (AREA)
NZ207622A 1983-03-24 1984-03-23 Xylane sulphates and pharmaceutical compositions NZ207622A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8305170A FR2543145B1 (fr) 1983-03-24 1983-03-24 Nouveaux sulfates de xylanes, leur procede de preparation et leur activite anti-thrombotique et hypolipemiante

Publications (1)

Publication Number Publication Date
NZ207622A true NZ207622A (en) 1986-08-08

Family

ID=9287351

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ207622A NZ207622A (en) 1983-03-24 1984-03-23 Xylane sulphates and pharmaceutical compositions

Country Status (16)

Country Link
US (1) US4699900A (ja)
EP (1) EP0125152B1 (ja)
JP (1) JPS6063203A (ja)
KR (1) KR860001394B1 (ja)
AT (1) ATE24520T1 (ja)
AU (1) AU561588B2 (ja)
CA (1) CA1221090A (ja)
DE (1) DE3461808D1 (ja)
DK (1) DK55784A (ja)
ES (1) ES8500962A1 (ja)
FR (1) FR2543145B1 (ja)
GR (1) GR79831B (ja)
IL (1) IL70846A0 (ja)
NZ (1) NZ207622A (ja)
PT (1) PT78179B (ja)
ZA (1) ZA842176B (ja)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2543145B1 (fr) * 1983-03-24 1986-10-17 Sanofi Sa Nouveaux sulfates de xylanes, leur procede de preparation et leur activite anti-thrombotique et hypolipemiante
FR2572731B1 (fr) * 1984-11-07 1987-03-06 Sanofi Sa Nouveaux sulfates de xylanes de bas poids moleculaires, leur procede de preparation et leur activite antithrombotique et hypolipemiante par voie orale
FR2574663B1 (fr) * 1984-12-17 1987-01-16 Sanofi Sa Nouvelle composition therapeutique a activite antithrombotique et hypolipemiante a base de xylanes et d'un acide organique
US4966890A (en) * 1986-04-04 1990-10-30 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US4820693A (en) * 1986-05-22 1989-04-11 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5484777A (en) * 1989-04-20 1996-01-16 Lange, Iii; Louis G. Pancreatic cholesterol esterase inhibitor
US5017565A (en) * 1989-04-20 1991-05-21 Lange Iii Louis G Use of sulfated polysaccharides to inhibit pancreatic cholesterol esterase
DE3917982A1 (de) * 1989-06-02 1990-12-06 Behringwerke Ag Verwendung von xylanpolyhydrogensulfaten zur therapie von zellproliferations-bedingten erkrankungen
FR2655267B1 (fr) * 1989-12-04 1992-04-03 Roussel Uclaf Nouveau derive sulfate du galactanne extrait de klebsiella, procede de preparation, application a titre de medicaments et compositions pharmaceutiques le renfermant.
US5141928B1 (en) * 1989-12-20 1995-11-14 Brujo Inc Ophthalmic medication
US5378829A (en) * 1990-04-23 1995-01-03 Akzo N.V. Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type
US5382570A (en) * 1990-04-23 1995-01-17 Akzo, N.V. Sulfated glycosaminoglycanoid derivatives of the dermatan sulfate and chondroitin sulfate type
US5668274A (en) * 1991-04-23 1997-09-16 Akzo Nobel N.V. Sulfated glycosaminoglycanoid derivatives of the dermatan sulfate and chondroitin sulfate type
IL102758A (en) * 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
US5639469A (en) * 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system
US6255295B1 (en) 1996-12-23 2001-07-03 Nutramax Laboratories, Inc. Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue
US6797289B2 (en) 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6451771B1 (en) 1999-02-12 2002-09-17 Nutramax Laboratories, Inc. Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
US20070141181A1 (en) * 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
ES2251289B1 (es) * 2004-02-27 2007-07-01 Bioiberica, S.A. Nuevo uso terapeutico de un grupo de polisacaridos sulfatados.
WO2009047699A1 (en) * 2007-10-10 2009-04-16 Alembic Limited An improved process for the preparation of an amorphous form of pentosan polysulfate or salts thereof
AU2008100725B4 (en) * 2008-07-04 2008-10-02 Parnell Technologies Pty Ltd A sulfated polysaccharide compound for clinical use
WO2011088418A2 (en) * 2010-01-15 2011-07-21 Mount Sinai School Of Medicine Inhibition of tnf-alpha induced activation of nfkb by pentosan polysulfate
WO2012101544A1 (en) * 2011-01-29 2012-08-02 Alembic Pharmaceuticals Limited An improved process for the preparation of pentosan polysulfate or salts thereof
WO2012114349A1 (en) * 2011-02-23 2012-08-30 Cadila Healthcare Limited An improved process for the preparation of pentosan polysulfate sodium
SG11202001824RA (en) 2016-08-31 2020-04-29 Oji Holdings Corp Production method for acidic xylooligosaccharide, and acidic xylooligosaccharide
JP6225321B1 (ja) 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
CA3065747A1 (en) 2017-05-31 2018-12-06 Oji Holdings Corporation Moisturizing composition comprising pentosan polysulfate
CA3075485A1 (en) * 2017-09-12 2019-03-21 Oji Holdings Corporation Pentosan polysulfate and method for producing pentosan polysulfate
KR102533822B1 (ko) * 2017-12-20 2023-05-17 오지 홀딩스 가부시키가이샤 폴리황산펜토산 및 폴리황산펜토산을 포함하는 의약

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH290145A (de) * 1944-06-13 1953-04-15 Kaulla Kurt Nikolai Dr Med Von Verfahren zur Herstellung von Schwefelsäureestern des Xylans.
FR1050576A (fr) * 1951-02-06 1954-01-08 Wander Ag Dr A Procédé pour la préparation de sels alcalins de l'ester sulfurique du xylane
US3290263A (en) * 1962-08-02 1966-12-06 Colonial Sugar Refining Co Process of reacting sugars with reagents wherein the sugar is dissolved in monohydric alcohols containing grouping
ES343957A1 (es) * 1967-08-09 1968-10-01 Rocador Sa Procedimiento de obtencion de polisacaridos sulfatados an- tilipemicos activos por via oral.
US4098995A (en) * 1976-07-12 1978-07-04 American Cyanamid Company Polygalactosido-sucrose poly(h-)sulfate salts
US4301153A (en) * 1977-03-21 1981-11-17 Riker Laboratories, Inc. Heparin preparation
US4122250A (en) * 1977-08-22 1978-10-24 Gottfried Schmer Separation of high-activity heparin by affinity chromatography
US4221907A (en) * 1979-07-09 1980-09-09 American Cyanamid Company Substituted O-α-D and O-β-D-multi-galactopyranosyl and glucopyranosyl 1→4 and 1→6 galactopyranosyl 1→6 α-D-glucopyranoses
DE2945595A1 (de) * 1979-11-12 1981-05-21 Sandoz-Patent-GmbH, 7850 Lörrach Verfahren zur herstellung von niedermolekularem heparin bzw. seinen salzen
US4281108A (en) * 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
FR2543145B1 (fr) * 1983-03-24 1986-10-17 Sanofi Sa Nouveaux sulfates de xylanes, leur procede de preparation et leur activite anti-thrombotique et hypolipemiante

Also Published As

Publication number Publication date
AU561588B2 (en) 1987-05-14
KR860001394B1 (ko) 1986-09-22
ZA842176B (en) 1984-10-31
AU2441284A (en) 1984-09-27
EP0125152B1 (fr) 1986-12-30
EP0125152A1 (fr) 1984-11-14
JPS6063203A (ja) 1985-04-11
US4699900A (en) 1987-10-13
ES530266A0 (es) 1984-11-01
CA1221090A (fr) 1987-04-28
IL70846A0 (en) 1984-05-31
KR840008376A (ko) 1984-12-14
ATE24520T1 (de) 1987-01-15
FR2543145A1 (fr) 1984-09-28
PT78179A (fr) 1984-04-01
GR79831B (ja) 1984-10-31
ES8500962A1 (es) 1984-11-01
DE3461808D1 (en) 1987-02-05
PT78179B (fr) 1986-04-24
DK55784D0 (da) 1984-02-08
FR2543145B1 (fr) 1986-10-17
DK55784A (da) 1984-09-25

Similar Documents

Publication Publication Date Title
NZ207622A (en) Xylane sulphates and pharmaceutical compositions
FI88046C (fi) Foerfarande foer framstaellning av hepariner med laog molekylvikt
US5013724A (en) Process for the sulfation of glycosaminoglycans, the sulfated glycosaminoglycans and their biological applications
US4713373A (en) Xylan sulfates of low molecular weight, process for their preparation and medicaments containing them
CA1171375A (en) Oligosaccharides having selective anticoagulation activity
US4474770A (en) Oligosaccharides having anti-Xa activity, pharmaceutical compositions containing them and method of use
JPS59133202A (ja) 解重合及び超硫酸化ヘパリン、その製造方法並びに製薬組成物
SK280642B6 (sk) N,o-sulfátované heparosany, spôsob ich prípravy a
JPH0588881B2 (ja)
JPH02206601A (ja) 抗トロンビン作用を有するオリゴサッカライドフラクションの製法
AU639427B2 (en) Novel dermatan sulfate and heparin oligosaccharides having antiatherosclerotic activity
CA2285383C (en) Glycosaminoglycans having high antithrombotic activity
US5519010A (en) Sulfated polysaccharide, pharmaceutically acceptable salt thereof, process for preparing same and medicament containing same as effective component
JP4267916B2 (ja) 多糖体ｋ５から誘導された高度のアンチトロンビン活性を有するグリコサミノグリカン及びその製法
WO1992002232A1 (en) Heparin fragment showing complement inhibition activity
JPH06510081A (ja) 血栓溶解活性を有するデルマタンスルフェート及びこれを含有する製薬形態
USRE35770E (en) Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them
AU2004259111B2 (en) Heparin-derived oligosaccharide mixtures, preparation thereof and pharmaceutical compositions containing said mixtures
IE56783B1 (en) Process for the depolymerisation and sulfation of polysaccharides
EP0408770B1 (en) New sulfated polysaccharide, pharmaceutically acceptable salts thereof, preparation thereof, and drug containing the same as active ingredient
Vijayabaskar et al. Low-molecular weight molluscan glycosaminoglycan from bivalve Katelysia opima (Gmelin)
JPS6219520A (ja) グリコサミノグリカンに基づく新規抗血栓剤、その調製法および薬剤組成物